Heart failure & cardiomyopathiesSecondary analysis
Efficacy of vericiguat by background guideline-directed medical therapy in the VICTOR trial
- Secondary analysis of the VICTOR randomised trial
- exploratory analysis
Authors' conclusion
In ambulatory patients with HFrEF receiving contemporary GDMT, we did not find convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for interaction testing.
Study context
- Population
- Ambulatory patients with heart failure with reduced ejection fraction (HFrEF) without recent worsening, by background guideline-directed medical therapy (GDMT)
- Participants
- 6,105 patients
- Comparison
- Vericiguat vs placebo, by background GDMT
- Primary endpoint
- CV death or first HF hospitalization
Primary result
As reported in the abstract
CV death or first HF hospitalization, by GDMT strata
Vericiguat vs PlaceboAdjusted hazard ratio (CI)
ARNI target-dose users
0.73(0.57–0.93)
any RAS target-dose users
0.77(0.64–0.93)
not meeting MRA target dose
0.67(0.48–0.95)
Further findings
CV death and all-cause death
- Patterns paralleled the primary endpoint
Baseline GDMT use
- Any ARNI/ACE/ARB
- 93.9%
- ARNI
- 56%
- SGLT2i
- 59%
- MRA
- 78%
- Beta-blocker
- 94%
Original publication
Efficacy of vericiguat by background guideline-directed medical therapy in the VICTOR trial. Eur J Heart Fail. Published 8 September 2026. doi:10.1093/ejhf/xuag294
Summarised from the published abstract; every number is checked against it